<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>HIV infection: Risk factors and prevention strategies</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">HIV infection: Risk factors and prevention strategies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">HIV infection: Risk factors and prevention strategies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myron S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roy M Gulick, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H525605781"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although the incidence of HIV has dropped considerably since the height of the epidemic, millions of new HIV infections occur globally each year. An understanding of the risk factors for HIV infection lies at the foundation of successful preventive strategies, which should combine both behavioral and biomedical interventions to reduce HIV infection risk.</p><p>This topic reviews these risk factors and prevention strategies. More detailed discussion on particular prevention strategies, including pre- and postexposure prophylaxis for HIV, and prevention of mother-to-child transmission of HIV are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a> and  <a class="medical medical_review" href="/z/d/html/3764.html" rel="external">"Management of health care personnel exposed to HIV"</a> and  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a> and  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H525605851"><span class="h1">MODES OF ACQUISITION</span><span class="headingEndMark"> — </span>HIV infection is acquired through sexual intercourse, exposure to infected blood, or perinatal transmission. The distribution of the modes of transmission of HIV infection varies in different countries. In the United States, male-to-male sexual contact and injection drug use (IDU) account for more than half of cases [<a href="#rid1">1</a>]. The estimated lifetime risk of an HIV diagnosis in the United States is 1 in 6 for all men who have sex with men (MSM), 1 in 2 for African American MSM, 1 in 4 for Latino MSM, 1 in 23 for women with IDU, and 1 in 36 for men with IDU, in contrast to 1 in 241 and 1 in 473 for heterosexual women and men, respectively [<a href="#rid2">2,3</a>].</p><p>In contrast, in some resource-limited areas, penile-vaginal intercourse is responsible for the majority of HIV infections, with a smaller but growing proportion of cases among MSM [<a href="#rid4">4</a>]. Stigma remains a major problem hindering the study of MSM in resource-constrained countries; the incidence and prevalence of HIV in MSM in these settings warrant greater attention. (See  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection", section on 'Modes of transmission driving the pandemic'</a>.)</p><p class="headingAnchor" id="H525605897"><span class="h1">RISK FACTORS FOR INFECTION</span><span class="headingEndMark"> — </span>Risk of HIV infection varies by type of sexual or parenteral exposure (<a class="graphic graphic_table graphicRef60145" href="/z/d/graphic/60145.html" rel="external">table 1</a>). However, estimates of risk are mostly based on observational studies and are difficult to quantify since transmission risk also depends on other cofactors that greatly enhance (and occasionally reduce) the probability of infection [<a href="#rid5">5-7</a>]. As an example, risk factors for HIV transmission include high viral load in the source patient, and risk factors for HIV acquisition after exposure include sexually transmitted infections (STIs), and lack of circumcision, as well as certain host and genetic factors [<a href="#rid8">8-10</a>]. </p><p class="headingAnchor" id="H3184227180"><span class="h2">Infectiousness of source</span></p><p class="headingAnchor" id="H525606004"><span class="h3">Viremia in the source individual and acute HIV</span><span class="headingEndMark"> — </span>For all modes of transmission, a higher viral load in the source individual living with HIV is associated with a greater risk of transmission. Viral load depends on several factors, most importantly whether the individual is taking antiretroviral therapy (ART) and the stage of HIV disease [<a href="#rid5">5,11,12</a>]. Individuals with stable viral suppression demonstrate no risk for HIV transmission [<a href="#rid11">11,13-18</a>]. Conversely, the risk of HIV transmission appears higher during acute infection, when HIV infection is unrecognized and maximal viremia is present [<a href="#rid5">5</a>]. Phylogenetic and modeling studies (further discussed below) have highlighted that transmission from acutely infected individuals contributes disproportionately to the spread of HIV. </p><p>In studies of heterosexual couples, those who transmit HIV have higher levels of HIV RNA than those who do not transmit HIV [<a href="#rid5">5,8,19,20</a>]. As an example, in a study of 415 HIV-serodiscordant couples in Uganda, the baseline serum viral load was higher among transmitting partners than non-transmitting partners (90,000 versus 38,000 copies/mL, respectively) [<a href="#rid8">8</a>]. For each log increase in viral load, there was a 2.5-fold increase in the risk of transmission. In contrast, there were no HIV transmission events from partners living with HIV whose baseline viral load was &lt;1500 copies/mL, suggesting a threshold viral level for transmission [<a href="#rid8">8</a>]. Accordingly, higher viral load in the genital secretions also increases the probability of HIV transmission [<a href="#rid19">19</a>]. Similar findings have been described for perinatal HIV transmission. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'HIV viremia and risk of infant infection'</a>.)</p><p>The viral load can be very high in patients with acute HIV infection or in those with advanced untreated AIDS [<a href="#rid21">21</a>]. Acute infection is also associated with increased viral shedding in genital secretions for several weeks after infection compared with the stable lower levels seen in chronic infection [<a href="#rid22">22</a>]. Accordingly, in several studies, the risk of transmission of HIV appears highest from patients with acute HIV infection and higher from patients with late-stage disease (ie, AIDS) compared with chronic infection [<a href="#rid21">21,23-27</a>]. One modeling study estimated that 38 percent of all HIV transmissions in Malawi were attributable to sexual contact with acutely infected individuals [<a href="#rid23">23</a>]. A phylogenetic analysis of patients with acute and early HIV infection, including mostly men who have sex with men, was similarly suggestive of transmission networks during early infection, with evidence of infection with viruses that could be grouped into closely related clusters [<a href="#rid24">24,25</a>]. Additionally, some animal data also support an increase in viral infectivity during newly-acquired infection [<a href="#rid28">28</a>]. </p><p class="headingAnchor" id="H3180981969"><span class="h3">Virus in genital fluids</span><span class="headingEndMark"> — </span>In general, lower levels of blood plasma HIV RNA are associated with decreased genital HIV RNA levels [<a href="#rid19">19</a>]. Several studies have shown that HIV can still be intermittently detected in seminal fluid of some men living with HIV, despite suppression of HIV viremia with ART [<a href="#rid29">29-33</a>]; this has been associated with concurrent STI, such as urethritis [<a href="#rid32">32</a>]. HIV can also often be detected in the vaginal secretions of women despite the use of ART that suppresses replication in blood [<a href="#rid34">34,35</a>]. However, when plasma RNA is suppressed, detectable viral RNA in genital fluids likely does not represent replication-competent virus capable of transmission. Several studies among women and men have demonstrated that treatment-induced viral suppression in the blood eliminates the risk of transmission. These studies are discussed in detail elsewhere. (See <a class="local">'Treatment as prevention'</a> below.)</p><p class="headingAnchor" id="H525606308"><span class="h3">Source with unknown HIV status</span><span class="headingEndMark"> — </span>Often the HIV status of the sexual or injecting partner is unknown. The probability of HIV acquisition from a source person whose HIV status is unknown is approximated by estimating the likelihood that the source has HIV multiplied by the likelihood of transmission. As an example, in the United States, the prevalence of HIV infection in men aged 18 to 39 in the NHANES study (2003 to 2006) was 0.43 percent [<a href="#rid36">36</a>]. Thus, the estimated risk of transmission following a single random episode of receptive vaginal intercourse in the United States would be approximated by multiplying 0.0043 times 0.001 for an estimate of 0.0000043 (ie, 1 in approximately 233,000). </p><p>However, specific information about the source may increase the likelihood that he or she is living with HIV (eg, a history of injection drug use). Furthermore, such calculations are completely different in parts of the world, such as many parts of sub-Saharan Africa, where HIV infection is far more prevalent.</p><p class="headingAnchor" id="H525606328"><span class="h2">Sexual transmission risk factors</span><span class="headingEndMark"> — </span>The exact risk of transmission of HIV with sexual exposure is incompletely defined [<a href="#rid5">5,6,37</a>]. However, the data do suggest that risk of HIV acquisition varies by type of exposure (ie, sexual acts) [<a href="#rid38">38-43</a>]. </p><p>The risk of acquiring HIV after rape by an unknown assailant depends on many factors specific to the assault. This issue is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2765.html" rel="external">"Evaluation and management of adult and adolescent sexual assault victims in the emergency department"</a>.)</p><p class="headingAnchor" id="H525606554"><span class="h3">Sexual behavior</span><span class="headingEndMark"> — </span>The risk of HIV transmission varies widely depending on the type of sexual exposure. In general, exposures that lead to mucosal disruption and bleeding are associated with higher risk than other exposures. Unprotected anal intercourse conveys the greatest probability of sexual transmission of HIV [<a href="#rid37">37</a>]. Other behavioral factors, such as whether condoms were used, the number of sexual partners, or sex under the influence of recreational drugs, also affect the overall risk of HIV infection. As an example, in a study of 3257 men who have sex with men (MSM) in six US cities, risk factors for HIV acquisition included history of a large number of sexual partners, unprotected receptive anal sex with a partner with an unknown HIV serostatus, and use of nitrate inhalants [<a href="#rid44">44</a>]. In sub-Saharan Africa, having a male sexual partner of older age is a risk of HIV acquisition among young women [<a href="#rid45">45</a>].</p><p>The risk of HIV transmission for different types of sexual exposure to HIV in discordant couples has been estimated using different methods (generally through modeling studies) and cohorts (<a class="graphic graphic_table graphicRef60145" href="/z/d/graphic/60145.html" rel="external">table 1</a>) [<a href="#rid46">46</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Receptive anal intercourse – One transmission per 72 sex acts </p><p class="bulletIndent1"><span class="glyph">●</span>Insertive anal intercourse – One transmission per 900 sex acts</p><p class="bulletIndent1"><span class="glyph">●</span>Receptive penile-vaginal intercourse – One transmission per 1250 sex acts </p><p class="bulletIndent1"><span class="glyph">●</span>Insertive penile-vaginal intercourse – One transmission per 2500 sex acts</p><p class="bulletIndent1"><span class="glyph">●</span>Receptive or insertive penile-oral sex – Zero to four transmissions per 10,000 sex acts</p><p></p><p>However, these risk estimates make it difficult to understand the magnitude of the HIV pandemic. Clinicians need to be aware that such estimates of risk are often based on studies of monogamous couples, among whom amplifying factors have been treated and repeated exposure may offer as yet unexplained protection from infection. There are scant empiric data on per contact risk of exposure. Additionally, differences in infectivity are also strongly influenced by the presence of other cofactors, such as concomitant genital ulcerative disease [<a href="#rid5">5</a>]. As an example, some models suggest that rates of HIV transmission may be as high as one transmission event for every three episodes of insertive anal sex between a male source with late-stage disease and a susceptible female with genital ulcerative disease [<a href="#rid47">47</a>]. Thus, using a single value for assessing risk of HIV transmission based on route of sexual exposure fails to reflect the variation associated with other important cofactors. </p><p>HIV transmission among MSM is generally higher than among heterosexual partners. Among heterosexual partners, male-to-female transmission may be slightly more common (ie, efficient) than female-to-male transmission, as observed for most STIs. The relative risk of male-to-female compared with female-to-male HIV transmission was well illustrated in one study of 563 HIV serodiscordant couples (including 156 females living with HIV and 400 males living with HIV), in which 19 male partners and 82 female partners acquired HIV during the course of observation [<a href="#rid48">48</a>]. This study suggested that male-to-female transmission was 1.9 times more efficient (95% CI 1.1-33) than female-to-male transmission.</p><p>Notably, female-to-female sexual transmission of HIV has only rarely been reported [<a href="#rid49">49,50</a>].</p><p class="headingAnchor" id="H525606697"><span class="h3">Lack of circumcision</span><span class="headingEndMark"> — </span>HIV acquisition rates among uncircumcised males are higher than for circumcised males. The biologic basis for this observation may be related to a high density of HIV target cells in male foreskin, including Langerhans cells and macrophages [<a href="#rid51">51</a>]. Randomized controlled trials in Africa have demonstrated that circumcision reduces the risk of female-to-male HIV transmission by 50 to 60 percent [<a href="#rid52">52-55</a>], and this benefit is sustained [<a href="#rid55">55</a>]. However, male circumcision of men living with HIV does not appear to decrease the risk of HIV transmission to the female partner, and efficacy in men who have sex with men has not been demonstrated. (See <a class="local">'Male circumcision'</a> below.)</p><p class="headingAnchor" id="H525606791"><span class="h3">Sexually transmitted infections</span><span class="headingEndMark"> — </span>Concurrent sexually transmitted infections (STIs) have been long known to increase the risk of both acquiring and transmitting HIV infection. The increased risk is widely acknowledged for STIs that cause genital ulcer disease but is also described with other STIs [<a href="#rid56">56</a>]. It has also been associated with the change in vaginal flora that characterizes bacterial vaginosis [<a href="#rid57">57,58</a>] and dysbiosis [<a href="#rid59">59</a>]. In particular, risk of HIV acquisition has been linked to specific inflammatory cytokine profiles evoked by STIs [<a href="#rid60">60</a>] and certain bacterial species that may compromise prevention strategies [<a href="#rid61">61</a>].</p><p>Several studies have demonstrated an increased incidence of HIV infection among patients with genital ulcerative diseases, such as herpes simplex virus and syphilis [<a href="#rid21">21,62,63</a>]. As an example, in a study of 174 monogamous Ugandan couples with discordant HIV serostatus, the probability of transmission was approximately four times higher in patients with genital ulceration compared to those without [<a href="#rid21">21</a>]. The effect of these infections on HIV risk is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8347.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus infection", section on 'HSV-2 and risk of HIV transmission'</a> and  <a class="medical medical_review" href="/z/d/html/7600.html" rel="external">"Syphilis in patients with HIV", section on 'Effect of syphilis on HIV'</a>.)</p><p>Increased risk of HIV is not limited to STIs that cause genital ulcer disease. In a prospective study of 242 South African women with high-risk sexual behavior, 28 became infected with HIV over 24 months [<a href="#rid64">64</a>]. Presence of a concurrent STI was associated with an increased risk of infection with HIV (hazard ratio [HR] 3.29, 95% CI 1.5-7.2). The incremental risk for HIV infection with <em>Neisseria gonorrhoeae</em> infection was greater than that with other infections (<em>Chlamydia trachomatis</em>, <em>Mycoplasma genitalium</em>, <em>Trichomonas vaginalis</em>). The majority of women with STIs were asymptomatic.</p><p>Among people with HIV infection, STIs may increase HIV shedding in genital secretions in spite of suppression of viremia with ART [<a href="#rid65">65-67</a>]. However, viral copies recovered are not likely to be replication competent. </p><p class="headingAnchor" id="H525607081"><span class="h3">Genetic background</span><span class="headingEndMark"> — </span>Similarity of HLA-class-I alleles between HIV discordant couples may affect the risk of transmission by resulting in selected viral strains that are more likely to escape the immune containment of the uninfected partner. In a study of serodiscordant couples, sharing of HLA-B alleles was associated with accelerated transmission of HIV after controlling for other variables (HR 2.23, 95% CI 1.52 to 3.26) [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/3987.html" rel="external">"Human leukocyte antigens (HLA): A roadmap"</a>). The most profound effects are mediated by the homozygous deletion of the CCR5 receptor [<a href="#rid68">68</a>]. People with this genetic variation are resistant to HIV because the CCR5 receptor is critical to HIV acquisition. Two patients who underwent bone marrow transplants with CCR5 deleted stem cells were cured of HIV infection, demonstrating the critical importance of this receptor [<a href="#rid69">69-71</a>]. (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Alterations in the CCR5 coreceptor'</a>.)</p><p class="headingAnchor" id="H525607113"><span class="h3">Hormonal contraceptive use</span><span class="headingEndMark"> — </span>Early studies raised concern that certain hormonal contraceptive methods, specifically depot <a class="drug drug_general" data-topicid="9600" href="/z/d/drug information/9600.html" rel="external">medroxyprogesterone acetate</a> (DPMA), might increase the risk of HIV acquisition. However, subsequent data suggest no increased risk of HIV among women using DPMA or other contraceptives. These studies are discussed in detail elsewhere [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/3753.html" rel="external">"HIV and women", section on 'Risk factors for HIV acquisition'</a>.)</p><p class="headingAnchor" id="H2706431423"><span class="h3">Other factors</span><span class="headingEndMark"> — </span>Studies observing higher incidence of HIV acquisition during late pregnancy and the postpartum period suggest the possibility that physiologic changes during pregnancy affect susceptibility to HIV infection [<a href="#rid73">73,74</a>]. There has also been increased interest in defining specific vaginal fluid cytokine profiles that are associated with and could serve as a marker for increased risk of HIV infection [<a href="#rid75">75,76</a>].</p><p class="headingAnchor" id="H525607141"><span class="h2">Bloodborne transmission risk factors</span><span class="headingEndMark"> — </span>The risk of transmission of HIV infection following inadvertent exposure varies widely depending upon the type of exposure. </p><p>The risk of HIV infection has been estimated for different types of bloodborne exposure to a source with HIV (<a class="graphic graphic_table graphicRef60145" href="/z/d/graphic/60145.html" rel="external">table 1</a>) [<a href="#rid7">7,77,78</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Blood transfusion – nine infections per 10 exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Needle or syringe sharing – one infection per 150 exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous needle-stick – one infection per 435 exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Mucous membrane exposure to blood (eg, splash to eye) – one infection per 1000 exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Other exposure (eg, human bite) – one infection per 25,000 exposures</p><p></p><p>Studies on needlestick injuries in the health care setting have identified certain characteristics of injury that are associated with increased risk of HIV infection [<a href="#rid79">79</a>]. These include a deep injury, injury with a device that was visibly contaminated with the source individual's blood, injury with a needle that had been placed in a vein or artery, and terminal illness in the source individual. The volume of blood contributes to the probability of transmission since the reported risk of HIV acquisition after transfusion with a contaminated unit of blood ranges from 88 to 100 percent [<a href="#rid7">7</a>]. With the current screening procedures for donated blood, this risk is vanishingly small (see  <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">"Blood donor screening: Laboratory testing", section on 'HIV-1 and HIV-2'</a>). In the United States, between 2000 and 2013, there has only been a single confirmed case of occupationally-acquired HIV infection among health care personnel, in a laboratory technician who had a needle puncture while working with live HIV culture [<a href="#rid80">80</a>].</p><p>The risk of HIV may be higher among individuals who inject drugs than is reflected by the risk of needle sharing. Many individuals who use injection drugs also participate in sexual behavior, such as unprotected sex and sex with multiple partners, that incrementally increases the risk for HIV infection [<a href="#rid81">81</a>]. </p><p class="headingAnchor" id="H525607218"><span class="h2">Perinatal transmission risk factors</span><span class="headingEndMark"> — </span>This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H525607681"><span class="h1">EFFICACY OF PREVENTION STRATEGIES</span></p><p class="headingAnchor" id="H525607687"><span class="h2">Postexposure prophylaxis</span><span class="headingEndMark"> — </span>For individuals who have a discrete high-risk exposure to HIV, postexposure prophylaxis with an antiretroviral-based regimen is an effective strategy to reduce the risk of infection. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3764.html" rel="external">"Management of health care personnel exposed to HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a>.)</p><p class="headingAnchor" id="H525607715"><span class="h2">Pre-exposure prophylaxis</span><span class="headingEndMark"> — </span>For individuals who are at ongoing high risk for HIV infection, pre-exposure prophylaxis with an antiretroviral-based regimen is an effective strategy to reduce the risk of infection. Pre-exposure prophylaxis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p class="headingAnchor" id="H525607733"><span class="h2">Treatment as prevention</span><span class="headingEndMark"> — </span>Treatment as prevention refers to the concept that successfully treating HIV with antiretroviral therapy (ART) minimizes the risk of transmission by decreasing the HIV plasma viral load, and it assumes the potential of a population level benefit.</p><p>Several studies have indicated that the risk of transmission to an uninfected sexual partner is negligible when an individual living with HIV has achieved durable viral suppression with ART [<a href="#rid82">82</a>]. This was best demonstrated in a large trial (HPTN 052) that included 1763 HIV serodiscordant heterosexual couples from 13 sites in 9 countries in Africa, Asia, South America, and North America [<a href="#rid12">12,83</a>]. The serodiscordant couples were randomly assigned to an "early ART" arm (initiation of HIV treatment at enrollment) or "delayed ART" arm (initiation of HIV treatment when the CD4 count dropped to less than 250 cells/microL or after an AIDS-related illness). ART consisted mainly of <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, and <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>. After 1.7 years of follow-up, interim analysis demonstrated that early ART substantially reduced the risk of HIV transmission to the partner compared with delayed ART (1 versus 27 linked transmissions, as determined by viral sequencing; hazard ratio [HR] 0.04, 95% CI 0.01-0.26). Following these results, ART was offered to the participants living with HIV in the delayed ART group who had not yet initiated it; by the end of the study, 96 percent of the delayed group had started on ART. After a median of 5.5 years and 8904 couple-years of follow-up, the prevention benefits were sustained: </p><p class="bulletIndent1"><span class="glyph">●</span>A total of 46 linked transmissions were identified. Three occurred in couples originally assigned to the early ART group compared with 43 in the delayed ART group (93 percent risk reduction with early ART). A total of eight linked transmissions occurred after the partner living with HIV had initiated ART, but they either occurred within three months of ART initiation or in the setting of ART failure. Thus, no linked transmission events occurred when the partner living with HIV had achieved stable viral suppression on ART.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There were an additional 16 HIV infections in each group. Of these, 14 in the early ART group and 12 in the delayed ART group were determined by viral sequencing to be genetically unlinked (ie, the source was not the individual's documented partner). An additional six infections (two in the early ART and four in the delayed ART group) could not be sequenced for technical reasons.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall, the incidence of HIV infection in the study was low (0.9 percent per year overall and 2.2 events per 100 person years in the delayed ART group at the interim analysis), which potentially reflects other risk reduction strategies in this study. All participants received condoms and risk reduction counseling. Complete adherence to condom use was independently associated with a reduced risk of both linked and unlinked HIV infections. </p><p></p><p>The efficacy of ART in reducing the risk of HIV transmission to an uninfected sexual partner has also been supported by many observational studies among heterosexual discordant couples [<a href="#rid13">13,14,84-92</a>]. As an example, in a large retrospective study of almost 39,000 such couples in China, the incidence of HIV infection among uninfected partners was lower if the infected partner was on ART versus untreated (1.3 versus 2.6 infections per 100 person years, respectively, adjusted HR 0.74, 95% CI 0.65–0.84) [<a href="#rid86">86</a>]. Similarly, in a large population-based prospective cohort study of individuals without HIV in rural KwaZulu-Natal, South Africa, where transmission is predominantly through heterosexual sex, HIV infection risk was lower in communities with high ART coverage compared with areas of low ART coverage [<a href="#rid93">93</a>]. Such ecological studies, which examine relationships between exposures and outcomes at the group level, have a number of methodological challenges, including selection bias, confounding, and assumptions about the time lag of effects, which limit the ability to link the exposure to the outcome for the individual [<a href="#rid87">87,94</a>]. Nevertheless, these results indicate the importance of ART as a prevention strategy. </p><p>Although most studies of treatment as prevention have included condom use counseling as part of the preventive strategy, studies evaluating serodiscordant couples who specifically do not use condoms also suggest that successful ART prevents transmission [<a href="#rid14">14-16</a>]. As an example, in a prospective observational study of serodiscordant (548 heterosexual and 340 men who have sex with men [MSM]) couples who chose not to use condoms and among whom the partner living with HIV was virally suppressed on ART (&lt;200 copies/mL), there were no documented intra-couple transmission events after more than 1200 couple-years of follow-up [<a href="#rid14">14</a>]. One heterosexual and 10 MSM partners acquired HIV infection during the study period, but viral sequence analysis suggested that these infections were not transmitted from the long-term partner living with HIV. </p><p>The efficacy of treatment as prevention is also reflected in the reduction in the rate of mother-to-child transmission of HIV with successful ART of the mother during pregnancy and delivery. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings", section on 'Efficacy of ART in preventing transmission'</a> and  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings", section on 'Individuals not on ART prior to pregnancy'</a>.)</p><p>Data on the efficacy of ART to prevent transmission in populations at risk for other modes of transmission (ie, MSM or injection drug users) are more limited:</p><p class="bulletIndent1"><span class="glyph">●</span>Several observational studies have suggested that ART prevents sexual transmission among MSM [<a href="#rid14">14-16</a>]. As an example, in a study of nearly 800 serodiscordant MSM couples in Europe, of which the partner living with HIV was virologically suppressed (viral load &lt;200 copies/mL) on ART, there were no linked transmissions over 1500 couple-years, which included over 76,000 condomless sex acts [<a href="#rid16">16</a>]. Over a third of men without HIV reported sex outside the partnership, and 15 incident unlinked infections were detected. Similarly, a study of nearly 350 MSM serodiscordant couples in Australia, Thailand, and Brazil did not detect any linked transmission over 232 couple-years, during which the infected partner was on suppressive ART (with a viral load &lt;200 copies/mL) [<a href="#rid15">15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of people who inject drugs in Indonesia, Vietnam, and the Ukraine, accelerated ART and substance use management reduced mortality and reduced HIV transmission among injection partners compared with standard of care (0 versus 7 incident infections, which were likely transmission events) [<a href="#rid95">95</a>].</p><p></p><p class="headingAnchor" id="H525608011"><span class="h3">Test and treat</span><span class="headingEndMark"> — </span>Given the impact of ART in eliminating HIV transmission between serodiscordant couples, there has been substantial interest in a strategy of early ART initiation upon diagnosis as a way to reduce community HIV incidence. Modeling studies have suggested that this "test-and-treat" strategy could significantly reduce HIV transmission in high prevalence countries [<a href="#rid96">96-98</a>], but randomized trials have yielded mixed results, with most demonstrating modest decrease in HIV incidence between intervention and control arms [<a href="#rid99">99-102</a>]. Trial interventions have included combinations of enhanced HIV testing, linkage to care, ART initiation, and adherence support. The magnitude of benefit at the population level requires complex interpretation. Some illustrative trials include the following: </p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in rural Uganda and Kenya (SEARCH Trial) that included over 150,000 participants, communities were randomly assigned to annual HIV testing with rapid ART initiation for those who test positive (intervention) compared with baseline HIV testing and ART administration according to national guidelines (control) [<a href="#rid101">101</a>]. All testing was performed in the setting of multi-disease public health fairs that also addressed hypertension and diabetes mellitus. The intervention resulted in higher rates of viral suppression (79 versus 68 percent at three years) and reduced mortality among individuals living with HIV (relative risk 0.77). However, it did not reduce the three-year cumulative incidence compared with the control group (0.77 versus 0.81 percent, relative risk 0.95, 95% CI 0.77-1.17); across both groups, annual HIV incidence decreased by 30 percent over three years. Marked improvement in the standard of care available to the control group over the course of the trial likely compromised the differences between groups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in Zambia and South Africa (PopART Trial) with greater than 48,000 participants, communities were randomly assigned to standard care or a prevention intervention of annual home-based HIV counseling and testing, linkage to care and adherence support for those who test positive, and encouragement of male circumcision [<a href="#rid102">102</a>]. Those in the prevention intervention group were further randomly assigned to universal ART or ART initiation according to local guidelines. Both intervention arms had increased rates of viral suppression compared to the standard care arm; however, only the intervention arm with ART provided per local guidelines had a lower HIV incidence compared with standard care (adjusted rate ratio for HIV incidence 0.70 [95% CI 0.55-0.88]). The reduction in HIV incidence with the prevention intervention and universal ART compared with standard care was lower in magnitude and not statistically significant (adjusted rate ratio 0.93 [95% CI 0.74-1.18]). When the two intervention arms were combined, there was a 20 percent decrease in HIV incidence relative to control communities. The explanation for the difference in HIV incidence reduction between the two prevention intervention groups is unclear.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A trial in rural and semi-urban areas in Botswana (Ya Tsie Trial) that included over 12,000 participants also demonstrated a 35 percent reduction in HIV incidence (0.59 versus 0.92 percent per year, incidence rate ratio 0.65, 95% CI 0.46-0.90) with annual HIV testing, enhanced linkage to care with early ART initiation, and encouragement of male circumcision [<a href="#rid100">100</a>]. </p><p></p><p>Further analyses of cost-effectiveness and projected population impact are also ongoing. These studies emphasize the degree of difficulty in treating the right people at the right time with the right drugs to get the maximal benefit of treatment as prevention. Untreated acute and early HIV transmission and migration of people off ART can be expected to lead to HIV transmission at a rate that would compromise the population benefit of a "Test and Treat" strategy. However, population surveys in African countries have demonstrated strong correlation between expansion of treatment of HIV and falling incidence of HIV infection [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H525608113"><span class="h2">Condom use</span><span class="headingEndMark"> — </span>Consistent condom use effectively decreases the risk of sexual HIV transmission and acquisition [<a href="#rid104">104-107</a>]. In 2009, a collaborative statement from the American College of Physicians and the HIV Medicine Association called for wider availability of condoms and education about their proper use to minimize the risk of HIV transmission [<a href="#rid107">107</a>]. In order for condom use to be effective in decreasing HIV prevalence, they need to be used consistently and with ongoing exposures, particularly in areas of high prevalence. </p><p>The majority of evidence for condom effectiveness is from observational studies. In a meta-analysis of 12 studies of HIV heterosexual serodiscordant couples, condom usage was classified in three categories: always, sometimes, or none [<a href="#rid104">104</a>]. HIV infection rates were much higher in those who never used condoms versus those who always did (6.7 versus 0.9 infections per 100 person years). A subsequent analysis of these studies suggested that condoms are 90 to 95 percent effective when used consistently [<a href="#rid108">108</a>]. A similar Cochrane review estimated that the consistent use of male latex condoms, defined as using a condom for all acts of penetrative vaginal intercourse, reduces HIV incidence by 80 percent, based on several longitudinal female-to-male and male-to-female serodiscordant couples [<a href="#rid106">106</a>]. Additionally, in a trial of ART to reduce HIV transmission within serodiscordant couples, a self-report of "100 percent use" of condoms compared with "less than 100 percent use" was associated with decreased HIV transmission (HR 0.35; 0.14-0.88) [<a href="#rid83">83</a>]. These clinical studies are consistent with the in vitro finding that latex and polyurethane condoms are impenetrable to HIV viral particles [<a href="#rid109">109</a>]. </p><p>Since women are often unable to convince their partners to use a condom, there is a need to assess other barrier methods that women can initiate. Female condoms are also impervious to viruses, including HIV; however, there are few clinical data regarding efficacy in prevention of HIV transmission [<a href="#rid110">110</a>]. </p><p class="headingAnchor" id="H525608279"><span class="h2">Male circumcision</span></p><p class="headingAnchor" id="H525608285"><span class="h3">HIV infection in heterosexual men</span><span class="headingEndMark"> — </span>Male circumcision reduces the risk of heterosexual men becoming infected with HIV. Voluntary male medical circumcision is generally safe, but rare cases of tetanus following circumcision have been reported in locations where uptake of infant tetanus immunization is low [<a href="#rid111">111,112</a>]. (See  <a class="medical medical_review" href="/z/d/html/5525.html" rel="external">"Tetanus"</a>.)</p><p>The efficacy of male circumcision to protect that male against HIV infection has been established by several randomized, controlled trials of circumcision conducted in Africa [<a href="#rid52">52-54</a>]. In these trials, men were randomly assigned to an intervention group, in which immediate circumcision was offered, or a control group, in which circumcision was delayed until the end of the study. In all cases, circumcisions were performed by clinicians experienced in the procedure and were rarely associated with moderate or severe adverse effects. These three trials were all ended early because of evidence of reduced HIV incidence in the intervention groups: </p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in Orange Farm, South Africa, circumcision reduced the risk of HIV infection by 60 percent among 3274 men aged 18 to 24 years (20 versus 48 new infections in the circumcision and control groups, respectively, after a mean follow-up of 18 months) [<a href="#rid52">52</a>]. The investigators controlled for behavioral factors, condom use, and health-seeking behaviors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in Kisumu, Kenya, circumcision reduced the risk of HIV infection by 53 percent among 2784 men aged 18 to 24 years (22 versus 47 new infections in the circumcision and control groups, respectively, after a median follow-up of 24 months) [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial in Rakai, Uganda, circumcision reduced the risk of HIV infection by 51 percent among 4996 men aged 15 to 49 years (0.66 versus 1.33 new infections per 100 person years in the circumcision and control groups, respectively, over 24 months) [<a href="#rid54">54</a>]. Following trial closure, the majority of uncircumcised men underwent circumcision. After five years, circumcision remained associated with a lower HIV risk (0.5 versus 1.93 new infections per 100 person years in circumcised and uncircumcised men, respectively) [<a href="#rid55">55</a>].</p><p></p><p>Population studies in Africa following wider availability and encouragement of voluntary medical male circumcision have also suggested an association between circumcision and reduced incidence of HIV infection and have continued to demonstrate safety of the practice [<a href="#rid92">92,113-115</a>]. </p><p>Data from the United States are limited. One study examined visit records of heterosexual African-American men who underwent HIV testing while attending STI clinics in Baltimore from 1993 to 2000 and analyzed the association between circumcision and the risk of HIV infection [<a href="#rid116">116</a>]. "Known" HIV risk was defined as patient notification by either their sexual partner or by an intervention specialist from the partner notification system of recent HIV exposure. Among 394 visits by patients with known exposure, circumcision was associated with lower HIV prevalence (10.2 percent versus 22 percent; adjusted prevalence rate ratio, 0.49 [95% CI 0.26-0.93]). In the United States, however, the majority of sexually-acquired HIV infections are among men who have sex with men (MSM), among whom circumcision has uncertain benefit with regard to HIV risk. (See <a class="local">'HIV infection in MSM'</a> below.)</p><p>Any policy to promote circumcision to protect against HIV infection needs to take into account cultural and human rights considerations, the risk of complications from the procedure performed in various settings, the prevalence of infection, and the potential to undermine existing protective behaviors and prevention strategies that reduce the risk of HIV infection [<a href="#rid53">53,117</a>]. Results from observational studies of men who underwent circumcision suggest that this prevention intervention is not necessarily offset by an adverse behavioral impact [<a href="#rid118">118,119</a>]. One study compared sexual behaviors of 324 recently circumcised and 324 uncircumcised Kenyan men at 1, 3, 6, 9, and 12 months after study enrollment [<a href="#rid118">118</a>]. Circumcised men did not engage in more risky behaviors.</p><p class="headingAnchor" id="H525608529"><span class="h3">HIV infection in women</span><span class="headingEndMark"> — </span>Although male circumcision reduces HIV acquisition in men, studies have not demonstrated a reduction in HIV acquisition among female sexual partners of men living with HIV who undergo circumcision. Results of these studies suggest that HIV transmission from men to their sexual partners reflects the HIV concentration in genital secretions (ie, semen) rather than exposure to the uncircumcised glans penis. </p><p>In a trial from Uganda, 922 men living with HIV with CD4 cell counts ≥350 cells were randomly assigned to immediate versus delayed circumcision for 24 months [<a href="#rid120">120</a>]. Circumcision did not reduce HIV transmission to the female sexual partners without HIV; over a 24-month period, the cumulative probability of female acquisition of HIV was 22 percent in the intervention group and 13 percent in the control group (adjusted HR 1.49, 0.52-3.57). In addition, excess HIV transmission occurred within the first six months in the male circumcision arm, particularly among those who resumed intercourse prior to wound healing. These findings suggest sexual abstinence or condom use should be strongly advised until surgical recovery (estimated at six weeks). </p><p class="headingAnchor" id="H525608549"><span class="h3">HIV infection in MSM</span><span class="headingEndMark"> — </span>To date, no randomized controlled studies of male circumcision for HIV prevention have been conducted among men who have sex with men (MSM). Observational studies have suggested a possible but uncertain protective effect. Because some (but not all) MSM engage in both insertive and receptive anal intercourse, it is difficult to conduct studies to show a benefit of circumcision in this setting.</p><p>In a meta-analysis performed of 15 observational studies among 53,567 MSM (52 percent of whom were circumcised), the odds of having HIV were 14 percent lower among the circumcised men, but the difference was not statistically significant [<a href="#rid121">121</a>]. </p><p class="headingAnchor" id="H525608569"><span class="h2">Counseling and harm reduction strategies</span><span class="headingEndMark"> — </span>Risk-reduction counseling and harm reduction strategies can reduce behavior that results in higher risk of HIV infection. Risk-reduction counseling ranges from high-intensity behavioral discussion tailored to an individual's risk to brief prevention messages to group-based strategies [<a href="#rid122">122,123</a>]. </p><p>Individuals report greater condom use and fewer sexual partners with behavioral risk-reduction interventions, and some studies report that counseling decreases risk of sexually transmitted infection (STI), including HIV [<a href="#rid124">124,125</a>]. The precise efficacy of risk-reduction counseling may depend, in part, on how it is conducted. (See  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Prevention counseling'</a>.)</p><p>For injection drug users, harm reduction interventions, such as voluntary opioid substitution therapy and needle exchange programs, can reduce risky injection behavior. Opioid substitution therapy is associated with decreased illicit opioid use, injecting use, and sharing injection equipment [<a href="#rid126">126</a>]. Needle exchange or supervised injection programs have also been associated with decreased needle reuse and sharing, safe syringe disposal, and more hygienic injection practices [<a href="#rid127">127</a>]. Although these strategies have not been evaluated in high-quality trials, observational and modeling studies suggest that they are associated with decreases in HIV infection [<a href="#rid126">126,128,129</a>]. Treatment of opioid addiction with <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">buprenorphine</a>/<a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> is also associated with increased use of and adherence to ART among individuals living with HIV [<a href="#rid130">130</a>]. As noted above, enhanced ART and substance abuse management have demonstrable personal and public health benefits [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H525608697"><span class="h2">Treatment of sexually transmitted infections</span><span class="headingEndMark"> — </span>"Classical" sexually transmitted infections (STIs) that cause ulcers or mucosal inflammation are strongly associated with HIV transmission [<a href="#rid56">56</a>]. However, it has been difficult to reliably demonstrate the benefits of STI treatment for HIV prevention [<a href="#rid131">131</a>]. Screening and treatment of STIs in at-risk individuals are important for general sexual health. (See  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Introduction'</a>.)</p><p>Population-based studies have generally been unable to show a decrease in HIV incidence with treatment or prevention of STIs [<a href="#rid132">132,133</a>]. It is generally concluded that STI treatment to prevent HIV infection requires treatment of just the right STI pathogen, at just the right time, with effective agents, goals that are not readily achieved. Additionally, the findings in these studies may reflect problems with methodology, patient adherence, and overlapping interventions in the control group in these studies as opposed to a true lack of preventive benefit with STI treatment [<a href="#rid131">131</a>].</p><p class="headingAnchor" id="H525608741"><span class="h2">Experimental approaches</span><span class="headingEndMark"> — </span>A vaccine to prevent HIV infection has been an elusive goal of HIV research. Despite several candidates, an effective HIV vaccine has yet to be developed [<a href="#rid134">134-136</a>]. However, new approaches continue to be investigated [<a href="#rid137">137,138</a>]. In addition, discovery and characterization of antibodies that neutralize a large number of strains of HIV have generated hope that such antibodies can be delivered or generated in some way to provide long-acting prevention from HIV [<a href="#rid139">139-143</a>].</p><p class="headingAnchor" id="H2237425918"><span class="h1">CLINICAL APPROACH TO HIV PREVENTION</span><span class="headingEndMark"> — </span>A comprehensive approach to HIV prevention includes risk reduction among individuals living with HIV to reduce transmission and among at-risk individuals to reduce acquisition. Biomedical interventions (such as the antiretroviral-based strategies of treatment as prevention and pre- and postexposure prophylaxis, as well as voluntary medical circumcision for uninfected heterosexual males) are proven and highly effective in reducing HIV infection. Nevertheless, behavioral interventions (such as condom use and risk-reduction counseling) remain crucial elements of prevention, and most studies of biomedical interventions included continued emphasis on behavioral modification. While no single behavioral intervention is perfectly effective, in aggregate, it is believed that such interventions have reduced the spread of HIV in some populations. The magnitude of the epidemic without such interventions cannot be predicted.</p><p>Accordingly, the following section discusses how certain aspects of biomedical and behavioral interventions are combined for a patient-specific approach. This discussion is generally consistent with recommendations on HIV prevention from multiple expert organizations [<a href="#rid144">144-146</a>]. Discussion of the studies supporting the individual prevention strategies is found elsewhere. (See <a class="local">'Efficacy of prevention strategies'</a> above.)</p><p class="headingAnchor" id="H2059972913"><span class="h2">Individuals living with HIV</span><span class="headingEndMark"> — </span>Preventing transmission of HIV from individuals living with HIV relies on engaging and maintaining patients living with HIV in care, initiating antiretroviral therapy (ART) early, maintaining successful therapy, and reducing behavioral risk factors. </p><p class="headingAnchor" id="H1732196031"><span class="h3">Antiretroviral treatment</span><span class="headingEndMark"> — </span>Suppression of plasma viremia with ART effectively minimizes the risk of sexual [<a href="#rid12">12,14,83,84</a>] and perinatal HIV transmission and likely does the same for other modes of transmission. Thus, ART is a key strategy to curb the spread of HIV. (See <a class="local">'Treatment as prevention'</a> above.)</p><p>In the United States, ART initiation is recommended for all patients living with HIV, regardless of CD4 cell count, to decrease AIDS and non-AIDS associated morbidities and mortalities [<a href="#rid144">144,146</a>]. Prevention of HIV transmission is an additional rationale for the more widespread use of ART. For resource-limited settings, the World Health Organization (WHO) has also recommended ART initiation for all patients living with HIV, regardless of CD4 cell count or clinical stage, given the mounting evidence of the clinical benefit of ART, even at high CD4 cell counts [<a href="#rid147">147,148</a>], and the reduction in the risk of transmission to uninfected partners with successful ART [<a href="#rid149">149</a>]. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/13980.html" rel="external">"Use and impact of antiretroviral therapy for HIV infection in resource-limited settings", section on 'Recommendations from the World Health Organization'</a>.)</p><p>Successful administration of ART relies upon public health measures to optimize timely linkage of newly diagnosed individuals living with HIV with medical care and retaining them in care. Treatment success also relies on patient adherence to medication, which can be facilitated by reductions in pill burden, reduced dosing frequency, and ongoing counseling to assess and encourage ART adherence. </p><p class="headingAnchor" id="H1946815802"><span class="h3">Counseling on condom use</span><span class="headingEndMark"> — </span>All patients living with HIV who are not on stable ART should use condoms to reduce the risk of sexual transmission. For individuals living with HIV with durable viral suppression on ART, the risk of transmission to an uninfected sexual partner is negligible and use of condoms for the purpose of preventing HIV transmission is no longer considered essential [<a href="#rid12">12,84,150</a>]. The extensive data supporting treatment for prevention has led to the "U=U" campaign, inspiring individuals living with HIV to recognize that "Undetectable" HIV in the blood as a result of successful ART leads to an "Untransmissible" status [<a href="#rid17">17</a>]. (See <a class="local">'Treatment as prevention'</a> above.) </p><p>Condoms do have other benefits, however, and we continue to advise their use in certain situations, including:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients at risk for other sexually transmitted infections (STIs), which are common among individuals living with HIV regardless of ART, and which condoms effectively prevent [<a href="#rid151">151</a>]. (See  <a class="medical medical_review" href="/z/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Male condom use'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When a partner living with HIV has loss of virologic suppression, in which case condoms can prevent against HIV transmission.</p><p></p><p class="headingAnchor" id="H355159304"><span class="h3">Risk reduction</span><span class="headingEndMark"> — </span>Routine assessment of ongoing risk behavior should be performed, and counseling on reducing those risks should be individualized. </p><p>For injection drug users, addiction treatment (eg, with opioid substitution or with buprenorphine-naltrexone) and participation in needle exchange programs, if available, are additional useful strategies to decrease risk behavior and, likely, HIV transmission. (See <a class="local">'Counseling and harm reduction strategies'</a> above.) </p><p>Finally, we screen and treat STIs in individuals living with HIV given the increased risk of STIs in this population, the association of STIs with HIV transmission, and the benefit of treating STIs beyond potential HIV prevention [<a href="#rid151">151</a>]. (See <a class="local">'Treatment of sexually transmitted infections'</a> above and  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Patients with HIV infection'</a>.)</p><p class="headingAnchor" id="H2662263261"><span class="h2">Individuals at risk for HIV</span></p><p class="headingAnchor" id="H2082024691"><span class="h3">Identifying new infections</span><span class="headingEndMark"> — </span>Identifying individuals living with HIV is crucial to directing interventions to prevent transmission. Thus, HIV testing is a major element of comprehensive preventive strategies. In particular, acutely infected individuals, who often have exceptionally high levels of viremia, have been identified as major sources of transmission (see <a class="local">'Viremia in the source individual and acute HIV'</a> above). Testing strategies should employ diagnostic tests that are highly sensitive for acute infection and should include routine screening for all individuals with repeat testing of individuals with high ongoing risk for HIV. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.) </p><p>Once HIV infection has been diagnosed or excluded, preventive efforts for that patient can be individualized. (See <a class="local">'Individuals living with HIV'</a> above and <a class="local">'Risk reduction'</a> below.)</p><p class="headingAnchor" id="H3343492836"><span class="h3">Risk reduction</span><span class="headingEndMark"> — </span>In uninfected individuals, preventing acquisition of HIV focuses on reducing behaviors that increase the risk of infection and utilizing antiretroviral-based prophylactic strategies. In areas where the prevalence of HIV is high and sexual transmission is primarily among heterosexuals, voluntary medical circumcision is another important strategy. </p><p>All uninfected patients should be assessed for their risk of HIV infection, and counseling on reducing those risks should be individualized. </p><p class="bulletIndent1"><span class="glyph">●</span>For all patients at risk for HIV infection, we continue to advise consistent condom use. (See <a class="local">'Condom use'</a> above.) </p><p></p><p class="bulletIndent1">We also recommend screening and treatment of STIs in individuals at risk for HIV given the shared risk factors for HIV and other STIs, the association of other STIs with HIV infection, and the benefit of treating STIs beyond potential HIV prevention [<a href="#rid151">151</a>]. (See <a class="local">'Treatment of sexually transmitted infections'</a> above and  <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">"Screening for sexually transmitted infections", section on 'Screening recommendations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For injection drug users, addiction treatment (eg, with opioid substitution or buprenorphine-naltrexone) and participation in needle exchange programs, if available, are additional useful strategies to decrease risk behavior and, likely, HIV acquisition. (See <a class="local">'Condom use'</a> above and <a class="local">'Counseling and harm reduction strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who have high ongoing risk for HIV infection, pre-exposure prophylaxis effectively reduces the risk of infection. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who have had a mucosal or parenteral exposure to HIV within the prior 72 hours, postexposure prophylaxis with an antiretroviral regimen is associated with a reduced risk of infection. (See  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults", section on 'Exposure to HIV'</a> and  <a class="medical medical_review" href="/z/d/html/3764.html" rel="external">"Management of health care personnel exposed to HIV", section on 'Post-exposure prophylaxis'</a>.) </p><p></p><p>Circumcision has demonstrated efficacy in reducing the risk of HIV infection among heterosexual men. WHO and the Joint United Nations Programme on HIV/AIDS (UNAIDS) recommend scaling up voluntary male circumcision as a HIV prevention intervention in several African countries with high rates of HIV and low baseline rates of male circumcision. In the United States and Europe, where sexual transmission among men who have sex with men (MSM) is dominant, circumcision has not demonstrated substantial benefit. (See <a class="local">'Male circumcision'</a> above.) </p><p class="headingAnchor" id="H3471690196"><span class="h2">Serodiscordant couples</span><span class="headingEndMark"> — </span>The term "serodiscordant couples" refers to ongoing sexual partnerships between an individual living with HIV and an uninfected individual. Prevention strategies for individuals living with HIV and at-risk individuals are thus relevant to each of the members of the serodiscordant couple, respectively. (See <a class="local">'Individuals living with HIV'</a> above and <a class="local">'Individuals at risk for HIV'</a> above.) </p><p>HIV transmission can be reduced with ART for the partner living with HIV [<a href="#rid12">12,83</a>] and with pre-exposure prophylaxis for the uninfected partner [<a href="#rid152">152</a>]. For all patients living with HIV in a serodiscordant partnership, we recommend initiation of ART in order to prevent transmission to the uninfected partner (see <a class="local">'Treatment as prevention'</a> above). No studies have directly compared the two strategies for HIV prevention, but ART for the partner living with HIV has the additional benefit of reducing the AIDS and non-AIDS morbidity and mortality for that individual [<a href="#rid83">83</a>]. Pre-exposure prophylaxis for the partner without HIV may be indicated until the partner living with HIV has achieved stable viral suppression on ART (typically by six months after initiating therapy [<a href="#rid153">153,154</a>]), if ART fails to suppress HIV in the partner living with HIV for any reason, and for risk-taking behavior outside the partnership. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Sexual risk'</a>.)</p><p>Counseling on condom use and other risk reduction strategies is discussed elsewhere. (See <a class="local">'Counseling on condom use'</a> above and <a class="local">'Risk reduction'</a> above.)</p><p>Options for serodiscordant couples desiring pregnancy are also discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7394.html" rel="external">"Use of assisted reproduction in HIV- and hepatitis-infected couples", section on 'Natural conception in serodiscordant couples'</a>.) </p><p class="headingAnchor" id="H952446874"><span class="h2">Pregnant and breastfeeding women</span><span class="headingEndMark"> — </span>Prevention of mother-to-child transmission of HIV involves ART for the pregnant woman and postexposure prophylaxis for the infant. Precise management differs in resource-rich and limited settings and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/15799.html" rel="external">"Antiretroviral selection and management in pregnant individuals with HIV in resource-rich settings"</a> and  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a> and  <a class="medical medical_review" href="/z/d/html/13970.html" rel="external">"Prevention of HIV transmission during breastfeeding in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H2821915580"><span class="h1">A PUBLIC HEALTH PLAN FOR THE UNITED STATES</span><span class="headingEndMark"> — </span>Utilizing the prevention interventions described below, the United States has described a plan to reduce incident HIV in the United States by 90 percent by 2030 [<a href="#rid155">155</a>]. The plan has "4 pillars":</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnose all individuals with HIV as early as possible after infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treat HIV rapidly and successfully to achieve sustained viral suppression</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prevent at-risk people from acquiring HIV through interventions including the use of pre-exposure prophylaxis</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapidly detect and respond to emerging clusters of HIV infection to further reduce new transmissions</p><p></p><p>This plan has a strong focus in the southern United States and some additional urban centers where HIV spread continues [<a href="#rid155">155</a>].</p><p class="headingAnchor" id="H3126338518"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111623.html" rel="external">"Society guideline links: HIV prevention"</a>.)</p><p class="headingAnchor" id="H525608759"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Modes of acquisition</strong> – HIV infection is acquired through sexual intercourse, exposure to infected blood, or perinatal transmission. For all modes of transmission, a higher viral load in the source individual living with HIV is associated with a greater risk of transmission. (See <a class="local">'Modes of acquisition'</a> above and <a class="local">'Viremia in the source individual and acute HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of sexual transmission</strong> – The risk of sexual transmission of HIV varies widely depending on the type of exposure. In general, exposures that lead to mucosal disruption and bleeding are associated with higher risk than other exposures. Unprotected anal sex conveys the greatest probability of HIV transmission and oral sex the lowest. Lack of circumcision is associated with HIV acquisition in men, and concurrent sexually transmitted infections are associated with both transmission and acquisition. Other behavioral factors, such as whether condoms were used, the number of sexual partners, and sex under the influence of recreational drugs, also affect overall sexual HIV transmission risk. (See <a class="local">'Sexual transmission risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk of parenteral transmission</strong> – The risk of parenteral transmission of HIV depends on the volume of contaminated blood that an individual is exposed to and the depth of the injury or exposure (eg, mucous membrane exposure, needle-stick, or injection into vessel). (See <a class="local">'Bloodborne transmission risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention strategies</strong> – A comprehensive approach to HIV prevention includes behavioral strategies (eg, harm reduction strategies such as condom use, opioid substitution therapy, needle exchange programs), antiretroviral-based strategies, screening and treatment of sexually transmitted infections (STIs), and in some settings, circumcision. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Behavioral interventions</strong> – Behavioral interventions (such as condom use and risk-reduction counseling for drug use) remain crucial elements of HIV prevention. In addition, continued condom use remains useful to reduce risk of other STIs. (See <a class="local">'Condom use'</a> above and <a class="local">'Counseling and harm reduction strategies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiretroviral therapy</strong> – Antiretroviral-based strategies to reduce HIV transmission are warranted for those with and without HIV infection.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Persons with HIV</strong> – For individuals living with HIV, successful antiretroviral therapy (ART) is a key strategy to prevent transmission. The risk of HIV transmission from an individual living with HIV who has achieved stable viral suppression to an uninfected partner is negligible. (See <a class="local">'Individuals living with HIV'</a> above and <a class="local">'Treatment as prevention'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Persons at risk for HIV</strong> – Antiretroviral-based strategies for persons without HIV can also reduce the risk of HIV acquisition. These include pre-exposure prophylaxis for individuals with ongoing risk, and post-exposure prophylaxis for those who have had a mucosal or parenteral exposure to HIV within the prior 72 hours. (See <a class="local">'Individuals at risk for HIV'</a> above and  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a> and  <a class="medical medical_review" href="/z/d/html/3768.html" rel="external">"Management of nonoccupational exposures to HIV and hepatitis B and C in adults"</a> and  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Approach for serodiscordant couples</strong> – For serodiscordant couples, we recommend antiretroviral treatment of the partner living with HIV as the primary prevention strategy instead of antiretroviral prophylaxis for the uninfected partner (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). Pre-exposure prophylaxis for the partner without HIV is additionally indicated until the infected partner has achieved stable viral suppression on ART (typically by six months after initiating therapy), if ART fails to suppress HIV in the partner living with HIV for any reason, or for risk-taking behavior outside the partnership. Management of serodiscordant couples desiring pregnancy is discussed elsewhere. (See <a class="local">'Serodiscordant couples'</a> above and  <a class="medical medical_review" href="/z/d/html/7394.html" rel="external">"Use of assisted reproduction in HIV- and hepatitis-infected couples", section on 'Natural conception in serodiscordant couples'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening for HIV and other sexually transmitted infections</strong> – For at-risk individuals, routine HIV screening and having a low threshold to test for HIV is crucial to identify new HIV infections and engage patients in interventions to prevent HIV transmission.</p><p></p><p class="bulletIndent2">We also screen for and treat other sexually transmitted infections in individuals with or at risk for HIV infection given the shared risk factors for HIV and other STIs, the association of other STIs with HIV infection, and the benefit of treating STIs beyond potential HIV prevention. (See <a class="local">'Treatment of sexually transmitted infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Circumcision</strong> – Circumcision has demonstrated efficacy in reducing the risk of HIV acquisition among heterosexual men, but the benefit among men who have sex with men (MSM) is uncertain. In areas where the prevalence of HIV is high and sexual transmission is mainly among heterosexuals, such as in several African countries, voluntary medical circumcision can be an effective element of HIV prevention intervention. (See <a class="local">'Male circumcision'</a> above.)</p><p></p><p class="headingAnchor" id="H3899453987"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Centers for Disease Control and Prevention. HIV Surveillance Report. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Accessed on August 08, 2018).</li><li><a class="nounderline abstract_t">Hess KL, Hu X, Lansky A, et al. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol 2017; 27:238.</a></li><li class="breakAll">Centers for Disease Control and Prevention. CDC Fact Sheet HIV among gay and bisexual men. https://www.cdc.gov/nchhstp/newsroom/docs/factsheets/cdc-msm-508.pdf (Accessed on November 18, 2019).</li><li class="breakAll">2020 Global AIDS Update ⁠— Seizing the moment ⁠— Tackling entrenched inequalities to end epidemics https://www.unaids.org/en/resources/documents/2020/global-aids-report (Accessed on December 09, 2020).</li><li><a class="nounderline abstract_t">Powers KA, Poole C, Pettifor AE, Cohen MS. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8:553.</a></li><li><a class="nounderline abstract_t">Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118.</a></li><li><a class="nounderline abstract_t">Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20:805.</a></li><li><a class="nounderline abstract_t">Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.</a></li><li><a class="nounderline abstract_t">Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149.</a></li><li><a class="nounderline abstract_t">Dorak MT, Tang J, Penman-Aguilar A, et al. Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples. Lancet 2004; 363:2137.</a></li><li><a class="nounderline abstract_t">Attia S, Egger M, Müller M, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23:1397.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med 2016; 375:830.</a></li><li><a class="nounderline abstract_t">Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375:2092.</a></li><li><a class="nounderline abstract_t">Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA 2016; 316:171.</a></li><li><a class="nounderline abstract_t">Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV 2018; 5:e438.</a></li><li><a class="nounderline abstract_t">Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet 2019; 393:2428.</a></li><li><a class="nounderline abstract_t">The Lancet Hiv . U=U taking off in 2017. Lancet HIV 2017; 4:e475.</a></li><li><a class="nounderline abstract_t">Cohen MS. Successful treatment of HIV eliminates sexual transmission. Lancet 2019; 393:2366.</a></li><li><a class="nounderline abstract_t">Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.</a></li><li><a class="nounderline abstract_t">Blaser N, Wettstein C, Estill J, et al. Impact of viral load and the duration of primary infection on HIV transmission: systematic review and meta-analysis. AIDS 2014; 28:1021.</a></li><li><a class="nounderline abstract_t">Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403.</a></li><li><a class="nounderline abstract_t">Pilcher CD, Joaki G, Hoffman IF, et al. Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007; 21:1723.</a></li><li><a class="nounderline abstract_t">Powers KA, Ghani AC, Miller WC, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 2011; 378:256.</a></li><li><a class="nounderline abstract_t">Pao D, Fisher M, Hué S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85.</a></li><li><a class="nounderline abstract_t">Volz EM, Ionides E, Romero-Severson EO, et al. HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis. PLoS Med 2013; 10:e1001568; discussion e1001568.</a></li><li><a class="nounderline abstract_t">Hollingsworth TD, Pilcher CD, Hecht FM, et al. High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California. J Infect Dis 2015; 211:1757.</a></li><li><a class="nounderline abstract_t">Marzel A, Shilaih M, Yang WL, et al. HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clin Infect Dis 2016; 62:115.</a></li><li><a class="nounderline abstract_t">Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288.</a></li><li><a class="nounderline abstract_t">Sheth PM, Kovacs C, Kemal KS, et al. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS 2009; 23:2050.</a></li><li><a class="nounderline abstract_t">Lambert-Niclot S, Tubiana R, Beaudoux C, et al. Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS 2012; 26:971.</a></li><li><a class="nounderline abstract_t">Pasquier C, Sauné K, Raymond S, et al. Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy. J Clin Microbiol 2009; 47:2883.</a></li><li><a class="nounderline abstract_t">Politch JA, Mayer KH, Welles SL, et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS 2012; 26:1535.</a></li><li><a class="nounderline abstract_t">Ghosn J, Leruez-Ville M, Blanche J, et al. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. Clin Infect Dis 2014; 58:1763.</a></li><li><a class="nounderline abstract_t">Cu-Uvin S, Caliendo AM, Reinert S, et al. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS 2000; 14:415.</a></li><li><a class="nounderline abstract_t">Neely MN, Benning L, Xu J, et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44:38.</a></li><li><a class="nounderline abstract_t">McQuillan GM, Kruszon-Moran D, Granade T, Feldman JW. Seroprevalence of HIV in the US Household Population Aged 18–49 Years: The National Health and Nutrition Examination Surveys, 1999–2006. J Acquir Immune Defic Syndr 2010; 53:117.</a></li><li><a class="nounderline abstract_t">Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol 2010; 39:1048.</a></li><li><a class="nounderline abstract_t">Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997; 336:1097.</a></li><li><a class="nounderline abstract_t">Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150:306.</a></li><li><a class="nounderline abstract_t">Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992; 5:1116.</a></li><li><a class="nounderline abstract_t">Rozenbaum W, Gharakhanian S, Cardon B, et al. HIV transmission by oral sex. Lancet 1988; 1:1395.</a></li><li><a class="nounderline abstract_t">Lazzarin A, Saracco A, Musicco M, Nicolosi A. Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1991; 151:2411.</a></li><li><a class="nounderline abstract_t">Seidlin M, Vogler M, Lee E, et al. Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS 1993; 7:1247.</a></li><li><a class="nounderline abstract_t">Buchbinder SP, Vittinghoff E, Heagerty PJ, et al. Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr 2005; 39:82.</a></li><li><a class="nounderline abstract_t">de Oliveira T, Kharsany AB, Gräf T, et al. Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study. Lancet HIV 2017; 4:e41.</a></li><li><a class="nounderline abstract_t">Patel P, Borkowf CB, Brooks JT, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 2014; 28:1509.</a></li><li><a class="nounderline abstract_t">Leynaert B, Downs AM, de Vincenzi I. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol 1998; 148:88.</a></li><li><a class="nounderline abstract_t">Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. BMJ 1992; 304:809.</a></li><li><a class="nounderline abstract_t">Chan SK, Thornton LR, Chronister KJ, et al. Likely female-to-female sexual transmission of HIV--Texas, 2012. MMWR Morb Mortal Wkly Rep 2014; 63:209.</a></li><li><a class="nounderline abstract_t">Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis 2003; 36:e40.</a></li><li><a class="nounderline abstract_t">Donoval BA, Landay AL, Moses S, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386.</a></li><li><a class="nounderline abstract_t">Auvert B, Taljaard D, Lagarde E, et al. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.</a></li><li><a class="nounderline abstract_t">Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643.</a></li><li><a class="nounderline abstract_t">Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657.</a></li><li><a class="nounderline abstract_t">Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 2012; 26:609.</a></li><li><a class="nounderline abstract_t">Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3.</a></li><li><a class="nounderline abstract_t">Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med 2012; 9:e1001251.</a></li><li><a class="nounderline abstract_t">Myer L, Denny L, Telerant R, et al. Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study. J Infect Dis 2005; 192:1372.</a></li><li><a class="nounderline abstract_t">Masson L, Barnabas S, Deese J, et al. Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study. Sex Transm Infect 2019; 95:5.</a></li><li><a class="nounderline abstract_t">Liebenberg LJ, Masson L, Arnold KB, et al. Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women. J Acquir Immune Defic Syndr 2017; 74:318.</a></li><li><a class="nounderline abstract_t">Klatt NR, Cheu R, Birse K, et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 2017; 356:938.</a></li><li><a class="nounderline abstract_t">Freeman EE, Weiss HA, Glynn JR, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73.</a></li><li><a class="nounderline abstract_t">Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006; 82:121.</a></li><li><a class="nounderline abstract_t">Mlisana K, Naicker N, Werner L, et al. Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa. J Infect Dis 2012; 206:6.</a></li><li><a class="nounderline abstract_t">Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. Sex Transm Dis 2008; 35:55.</a></li><li><a class="nounderline abstract_t">Sadiq ST, Taylor S, Kaye S, et al. The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis. AIDS 2002; 16:219.</a></li><li><a class="nounderline abstract_t">Chen JS, Matoga M, Massa C, et al. Effects of Urethritis on Human Immunodeficiency Virus (HIV) in Semen: Implications for HIV Prevention and Cure. Clin Infect Dis 2021; 73:e2000.</a></li><li><a class="nounderline abstract_t">Simmons G, Wilkinson D, Reeves JD, et al. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J Virol 1996; 70:8355.</a></li><li><a class="nounderline abstract_t">Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature 2019; 568:244.</a></li><li><a class="nounderline abstract_t">Bauer G, Anderson JS. Stem cell transplantation in the context of HIV--how can we cure HIV infection? Expert Rev Clin Immunol 2014; 10:107.</a></li><li><a class="nounderline abstract_t">Hütter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692.</a></li><li><a class="nounderline abstract_t">Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. Lancet 2019; 394:303.</a></li><li><a class="nounderline abstract_t">Thomson KA, Hughes J, Baeten JM, et al. Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners. J Infect Dis 2018; 218:16.</a></li><li><a class="nounderline abstract_t">Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis. PLoS Med 2014; 11:e1001608.</a></li><li><a class="nounderline abstract_t">Masson L, Passmore JA, Liebenberg LJ, et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 2015; 61:260.</a></li><li><a class="nounderline abstract_t">Selhorst P, Masson L, Ismail SD, et al. Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants. Clin Infect Dis 2017; 64:79.</a></li><li><a class="nounderline abstract_t">Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005; 54:1.</a></li><li><a class="nounderline abstract_t">Kaplan EH, Heimer R. HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:175.</a></li><li><a class="nounderline abstract_t">Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997; 337:1485.</a></li><li><a class="nounderline abstract_t">Joyce MP, Kuhar D, Brooks JT. Notes from the field: occupationally acquired HIV infection among health care workers - United States, 1985-2013. MMWR Morb Mortal Wkly Rep 2015; 63:1245.</a></li><li><a class="nounderline abstract_t">Spiller MW, Broz D, Wejnert C, et al. HIV infection and HIV-associated behaviors among persons who inject drugs--20 cities, United States, 2012. MMWR Morb Mortal Wkly Rep 2015; 64:270.</a></li><li><a class="nounderline abstract_t">LeMessurier J, Traversy G, Varsaneux O, et al. Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review. CMAJ 2018; 190:E1350.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.</a></li><li><a class="nounderline abstract_t">Muessig KE, Cohen MS. Advances in HIV prevention for serodiscordant couples. Curr HIV/AIDS Rep 2014; 11:434.</a></li><li><a class="nounderline abstract_t">Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20:85.</a></li><li><a class="nounderline abstract_t">Jia Z, Mao Y, Zhang F, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet 2013; 382:1195.</a></li><li><a class="nounderline abstract_t">Supervie V, Viard JP, Costagliola D, Breban R. Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling. Clin Infect Dis 2014; 59:115.</a></li><li><a class="nounderline abstract_t">Jean K, Gabillard D, Moh R, et al. Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire. J Infect Dis 2014; 209:431.</a></li><li><a class="nounderline abstract_t">Anglemyer A, Rutherford GW, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011; :CD009153.</a></li><li><a class="nounderline abstract_t">Smith MK, Westreich D, Liu H, et al. Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012. Clin Infect Dis 2015; 61:111.</a></li><li><a class="nounderline abstract_t">Oldenburg CE, Bärnighausen T, Tanser F, et al. Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa. Clin Infect Dis 2016; 63:548.</a></li><li><a class="nounderline abstract_t">Grabowski MK, Serwadda DM, Gray RH, et al. HIV Prevention Efforts and Incidence of HIV in Uganda. N Engl J Med 2017; 377:2154.</a></li><li><a class="nounderline abstract_t">Tanser F, Bärnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966.</a></li><li><a class="nounderline abstract_t">Smith MK, Powers KA, Muessig KE, et al. HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med 2012; 9:e1001260.</a></li><li><a class="nounderline abstract_t">Miller WC, Hoffman IF, Hanscom BS, et al. A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study. Lancet 2018; 392:747.</a></li><li><a class="nounderline abstract_t">Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.</a></li><li><a class="nounderline abstract_t">Abbas UL. Uptake of biomedical interventions for prevention of sexually transmitted HIV. Curr Opin HIV AIDS 2011; 6:114.</a></li><li><a class="nounderline abstract_t">Palombi L, Bernava GM, Nucita A, et al. Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level. Clin Infect Dis 2012; 55:268.</a></li><li><a class="nounderline abstract_t">Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV 2018; 5:e116.</a></li><li><a class="nounderline abstract_t">Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med 2019; 381:230.</a></li><li><a class="nounderline abstract_t">Havlir DV, Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med 2019; 381:219.</a></li><li><a class="nounderline abstract_t">Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). N Engl J Med 2019; 381:207.</a></li><li><a class="nounderline abstract_t">Justman JE, Mugurungi O, El-Sadr WM. HIV Population Surveys - Bringing Precision to the Global Response. N Engl J Med 2018; 378:1859.</a></li><li><a class="nounderline abstract_t">Davis KR, Weller SC. The effectiveness of condoms in reducing heterosexual transmission of HIV. Fam Plann Perspect 1999; 31:272.</a></li><li><a class="nounderline abstract_t">Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82:454.</a></li><li><a class="nounderline abstract_t">Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; :CD003255.</a></li><li><a class="nounderline abstract_t">Lubinski C, Aberg J, Bardeguez AD, et al. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis 2009; 48:1335.</a></li><li><a class="nounderline abstract_t">Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med 1997; 44:1303.</a></li><li><a class="nounderline abstract_t">Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1987; 1:49.</a></li><li><a class="nounderline abstract_t">Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17:110.</a></li><li><a class="nounderline abstract_t">Grund JM, Toledo C, Davis SM, et al. Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015. MMWR Morb Mortal Wkly Rep 2016; 65:36.</a></li><li class="breakAll">WHO Informal consultation on tetanus and voluntary medical male circumcision, Technical consultation update to the WHO March 2015 meeting report. June 2016. http://www.who.int/hiv/pub/malecircumcision/male-circumcision-2016-update/en/ (Accessed on May 02, 2017).</li><li><a class="nounderline abstract_t">Auvert B, Taljaard D, Rech D, et al. Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys. PLoS Med 2013; 10:e1001509.</a></li><li><a class="nounderline abstract_t">Kigozi G, Musoke R, Kighoma N, et al. Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda. Urology 2014; 83:294.</a></li><li><a class="nounderline abstract_t">Kong X, Kigozi G, Ssekasanvu J, et al. Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda. JAMA 2016; 316:182.</a></li><li><a class="nounderline abstract_t">Warner L, Ghanem KG, Newman DR, et al. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis 2009; 199:59.</a></li><li><a class="nounderline abstract_t">Sawires SR, Dworkin SL, Fiamma A, et al. Male circumcision and HIV/AIDS: challenges and opportunities. Lancet 2007; 369:708.</a></li><li><a class="nounderline abstract_t">Agot KE, Kiarie JN, Nguyen HQ, et al. Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision. J Acquir Immune Defic Syndr 2007; 44:66.</a></li><li><a class="nounderline abstract_t">Kong X, Kigozi G, Nalugoda F, et al. Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda. Am J Epidemiol 2012; 176:875.</a></li><li><a class="nounderline abstract_t">Wawer MJ, Makumbi F, Kigozi G, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 2009; 374:229.</a></li><li><a class="nounderline abstract_t">Millett GA, Flores SA, Marks G, et al. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA 2008; 300:1674.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Effective interventions: HIV prevention that works. https://effectiveinterventions.cdc.gov/en/HighImpactPrevention/Interventions.aspx (Accessed on June 16, 2015).</li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Scott-Sheldon LA, Huedo-Medina TB, Warren MR, et al. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. J Acquir Immune Defic Syndr 2011; 58:489.</a></li><li><a class="nounderline abstract_t">Eaton LA, Huedo-Medina TB, Kalichman SC, et al. Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages. Am J Public Health 2012; 102:e34.</a></li><li><a class="nounderline abstract_t">Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; :CD004145.</a></li><li><a class="nounderline abstract_t">Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf) 2007; 29:35.</a></li><li><a class="nounderline abstract_t">Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; 376:268.</a></li><li><a class="nounderline abstract_t">Neaigus A, Zhao M, Gyarmathy VA, et al. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health 2008; 85:309.</a></li><li><a class="nounderline abstract_t">Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 2011; 56 Suppl 1:S22.</a></li><li><a class="nounderline abstract_t">Stillwaggon E, Sawers L. Rush to judgment: the STI-treatment trials and HIV in sub-Saharan Africa. J Int AIDS Soc 2015; 18:19844.</a></li><li><a class="nounderline abstract_t">Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24:621.</a></li><li><a class="nounderline abstract_t">Kaul R, Kimani J, Nagelkerke NJ, et al. Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial. JAMA 2004; 291:2555.</a></li><li><a class="nounderline abstract_t">Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661.</a></li><li><a class="nounderline abstract_t">Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654.</a></li><li><a class="nounderline abstract_t">Gray GE, Bekker LG, Laher F, et al. Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med 2021; 384:1089.</a></li><li><a class="nounderline abstract_t">Rosengarten JF, Schatz S, Wolf T, et al. Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes. Virology 2022; 568:41.</a></li><li><a class="nounderline abstract_t">Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines-Progress and Future Paths. Vaccines (Basel) 2021; 9.</a></li><li><a class="nounderline abstract_t">Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science 2014; 345:169.</a></li><li><a class="nounderline abstract_t">Burton DR, Mascola JR. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 2015; 16:571.</a></li><li><a class="nounderline abstract_t">Burton DR, Ahmed R, Barouch DH, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012; 12:396.</a></li><li><a class="nounderline abstract_t">Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015; 522:487.</a></li><li><a class="nounderline abstract_t">Corey L, Gilbert PB, Juraska M, et al. Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med 2021; 384:1003.</a></li><li class="breakAll">United States Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines (Accessed on November 23, 2020).</li><li class="breakAll">https://www.who.int/publications/guidelines/hiv_aids/en/ (Accessed on December 09, 2020).</li><li><a class="nounderline abstract_t">Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA 2020; 324:1651.</a></li><li><a class="nounderline abstract_t">TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.</a></li><li><a class="nounderline abstract_t">INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.</a></li><li class="breakAll">World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, second edition. June 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/ (Accessed on June 15, 2016).</li><li><a class="nounderline abstract_t">Eshleman SH, Hudelson SE, Redd AD, et al. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 2017; 74:112.</a></li><li><a class="nounderline abstract_t">Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. Sex Transm Infect 2011; 87:183.</a></li><li><a class="nounderline abstract_t">Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.</a></li><li><a class="nounderline abstract_t">Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807.</a></li><li><a class="nounderline abstract_t">Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679.</a></li><li><a class="nounderline abstract_t">Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV Epidemic: A Plan for the United States. JAMA 2019; 321:844.</a></li></ol></div><div id="topicVersionRevision">Topic 16612 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Centers for Disease Control and Prevention. HIV Surveillance Report. https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Accessed on August 08, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325538" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Lifetime risk of a diagnosis of HIV infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325538" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Lifetime risk of a diagnosis of HIV infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28325538" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lifetime risk of a diagnosis of HIV infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18684670" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19179227" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549963" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738050" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11323041" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15220037" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19381076" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424812" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Antiretroviral Therapy for the Prevention of HIV-1 Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20537376" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404185" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30025681" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31056293" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096785" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : U=U taking off in 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31056290" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Successful treatment of HIV eliminates sexual transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21471433" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24691205" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Impact of viral load and the duration of primary infection on HIV transmission: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809897" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690570" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684591" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15627037" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339751" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : HIV-1 transmission during early infection in men who have sex with men: a phylodynamic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25542958" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : High Transmissibility During Early HIV Infection Among Men Who Have Sex With Men-San Francisco, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387084" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129448" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710596" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22382146" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19641060" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Determining seminal plasma human immunodeficiency virus type 1 load in the context of efficient highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441253" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647014" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770544" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17106279" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19710616" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Seroprevalence of HIV in the US Household Population Aged 18–49 Years: The National Health and Nutrition Examination Surveys, 1999–2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406794" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9091810" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430236" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Per-contact risk of human immunodeficiency virus transmission between male sexual partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1403641" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A model-based estimate of HIV infectivity via needle sharing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2898067" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : HIV transmission by oral sex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684098" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Man-to-woman sexual transmission of the human immunodeficiency virus. Risk factors related to sexual behavior, man's infectiousness, and woman's susceptibility. Italian Study Group on HIV Heterosexual Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8216983" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Heterosexual transmission of HIV in a cohort of couples in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15851918" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27914874" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transmission networks and risk of HIV infection in KwaZulu-Natal, South Africa: a community-wide phylogenetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24809629" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Estimating per-act HIV transmission risk: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9663408" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1392708" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622284" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Likely female-to-female sexual transmission of HIV--Texas, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539088" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Female-to-female transmission of human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16613341" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16231970" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321310" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321311" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22210632" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10448335" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22745608" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16170754" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30018088" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Inflammatory cytokine biomarkers of asymptomatic sexually transmitted infections and vaginal dysbiosis: a multicentre validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28187085" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Genital-Systemic Chemokine Gradients and the Risk of HIV Acquisition in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28572388" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16327322" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16581736" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22517910" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Symptomatic vaginal discharge is a poor predictor of sexually transmitted infections and genital tract inflammation in high-risk women in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18217225" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11807306" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The effects of antiretroviral therapy on HIV-1 RNA loads in seminal plasma in HIV-positive patients with and without urethritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33033831" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effects of Urethritis on Human Immunodeficiency Virus (HIV) in Semen: Implications for HIV Prevention and Cure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8970955" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30836379" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24308835" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Stem cell transplantation in the context of HIV--how can we cure HIV infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19213682" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31204114" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514254" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586123" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Incident HIV during pregnancy and postpartum and risk of mother-to-child HIV transmission: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25900168" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Genital inflammation and the risk of HIV acquisition in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27694480" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15660015" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7552482" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : HIV incidence among New Haven needle exchange participants: updated estimates from syringe tracking and testing data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9366579" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25577991" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Notes from the field: occupationally acquired HIV infection among health care workers - United States, 1985-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25789742" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : HIV infection and HIV-associated behaviors among persons who inject drugs--20 cities, United States, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455270" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Risk of sexual transmission of human immunodeficiency virus with antiretroviral therapy, suppressed viral load and condom use: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767103" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prevention of HIV-1 infection with early antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145645" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Advances in HIV prevention for serodiscordant couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16327323" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23206835" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24723286" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23990567" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21563172" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25770173" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27208044" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Antiretroviral Therapy to Prevent HIV Acquisition in Serodiscordant Couples in a Hyperendemic Community in Rural South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29171817" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : HIV Prevention Efforts and Incidence of HIV in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430656" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22802740" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : HIV treatment as prevention: the utility and limitations of ecological observation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30191830" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038438" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21505385" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Uptake of biomedical interventions for prevention of sexually transmitted HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22491503" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29199100" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314967" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314966" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314965" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768142" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : HIV Population Surveys - Bringing Precision to the Global Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10614517" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The effectiveness of condoms in reducing heterosexual transmission of HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356939" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effectiveness of condoms in preventing sexually transmitted infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11869658" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Condom effectiveness in reducing heterosexual HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19385087" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141163" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effectiveness of condoms in preventing HIV transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3122790" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2163113" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Evaluation of the virus permeability of a new condom for women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797167" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26797167" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019763" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Association of the ANRS-12126 male circumcision project with HIV levels among men in a South African township: evaluation of effectiveness using cross-sectional surveys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24286598" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27404186" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Association of Medical Male Circumcision and Antiretroviral Therapy Scale-up With Community HIV Incidence in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19086815" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17321321" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Male circumcision and HIV/AIDS: challenges and opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17019365" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Male circumcision in Siaya and Bondo Districts, Kenya: prospective cohort study to assess behavioral disinhibition following circumcision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23097257" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Assessment of changes in risk behaviors during 3 years of posttrial follow-up of male circumcision trial participants uncircumcised at trial closure in Rakai, Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616720" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840841" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18840841" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22083038" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22994247" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Meta-analysis of single-session behavioral interventions to prevent sexually transmitted infections: implications for bundling prevention packages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21833948" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Oral substitution treatment of injecting opioid users for prevention of HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17229788" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Changes in injecting practices associated with the use of a medically supervised safer injection facility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20650523" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : HIV and risk environment for injecting drug users: the past, present, and future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18340537" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317590" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25990095" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Rush to judgment: the STI-treatment trials and HIV in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179575" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Weighing the gold in the gold standard: challenges in HIV prevention research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173146" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Monthly antibiotic chemoprophylaxis and incidence of sexually transmitted infections and HIV-1 infection in Kenyan sex workers: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109337" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15688278" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761206" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35101772" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Components of a HIV-1 vaccine mediate virus-like particle (VLP)-formation and display of envelope proteins exposing broadly neutralizing epitopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33562203" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : HIV mRNA Vaccines-Progress and Future Paths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25013067" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Immunologic strategies for HIV-1 remission and eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988889" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Antibody responses to envelope glycoproteins in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23084910" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A Blueprint for HIV Vaccine Discovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855300" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730454" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730454" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33730454" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33052386" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193126" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192873" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192873" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27532476" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330572" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784037" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24195548" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19487905" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30730529" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Ending the HIV Epidemic: A Plan for the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
